Zura Bio Limited (NASDAQ:ZURA) Short Interest Up 28.1% in September

Zura Bio Limited (NASDAQ:ZURA) saw a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 849,700 shares, a growth of 28.1% from the August 31st total of 663,300 shares. Based on an average daily trading volume, of 471,000 shares, the days-to-cover ratio is presently 1.8 days. Currently, 2.0% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

ZURA has been the subject of a number of recent analyst reports. Piper Sandler restated an “overweight” rating and set a $26.00 target price on shares of Zura Bio in a report on Thursday, September 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a research note on Thursday, August 15th. Finally, HC Wainwright began coverage on shares of Zura Bio in a research note on Thursday, September 5th. They issued a “neutral” rating and a $5.00 price target for the company. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $15.50.

Insider Activity at Zura Bio

In other Zura Bio news, Director Someit Sidhu sold 51,728 shares of the firm’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total value of $200,187.36. Following the sale, the director now owns 2,085,418 shares of the company’s stock, valued at approximately $8,070,567.66. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 15.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ZURA. Point72 Asset Management L.P. purchased a new position in shares of Zura Bio in the second quarter worth $8,446,000. Great Point Partners LLC increased its position in Zura Bio by 68.3% during the second quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock valued at $16,248,000 after acquiring an additional 1,884,501 shares during the last quarter. Armistice Capital LLC lifted its stake in shares of Zura Bio by 53.2% in the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock worth $8,834,000 after purchasing an additional 876,000 shares during the period. Affinity Asset Advisors LLC bought a new stake in Zura Bio during the first quarter valued at approximately $1,157,000. Finally, AQR Capital Management LLC purchased a new stake in shares of Zura Bio in the 2nd quarter worth $43,000. Institutional investors own 61.14% of the company’s stock.

Zura Bio Price Performance

Shares of Zura Bio stock opened at $4.07 on Friday. Zura Bio has a 12 month low of $2.00 and a 12 month high of $7.22. The business has a fifty day simple moving average of $3.77 and a two-hundred day simple moving average of $3.80.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). On average, sell-side analysts anticipate that Zura Bio will post -0.47 earnings per share for the current year.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.